[MCQ] Parkinson’s Disease (PD) and Other Movement Disorders- Part 3

I. Start the exam by click the “Start” button

Parkinson’s Disease (PD) and Other Movement Disorders- Part 3

Please wait while the activity loads.
If this activity does not load, try refreshing your browser. Also, this page requires javascript. Please visit using a browser with javascript enabled.

If loading fails, click here to try again

Start

Congratulations - you have completed Parkinson’s Disease (PD) and Other Movement Disorders- Part 3. You scored %%SCORE%% out of %%TOTAL%%. Your performance has been rated as %%RATING%%

Your answers are highlighted below.

Question 1

Which of the following symptom precedes onset of PD ?

A	Rapid eye movement - behavioral disorder (RBD)
B	Micrographia
C	Hypophonia
D	All of the above

Question 1 Explanation:

Restless legs and rapid eye movement–behavioral disorder (RBD) often preceed the onset of PD

Question 2

Cause of neuropsychiatric symptoms in PD can be ?

A	Accompanying Alzheimer’s disease (AD)
B	Accompanying cortical dementia with Lewy bodies (DLB)
C	Side effect of pharmacotherapy
D	All of the above

Question 2 Explanation:

Neuropsychiatric symptoms of later stages of PD may be direct result of PD or accompanying Alzheimer’s disease, cortical dementia with Lewy bodies or as a side effect of its drugs.

Question 3

Predictors of dementia in PD include all except ?

A	Early age of onset
B	Akinetic rigid phenotype
C	Presence of severe depression
D	Persistent hallucinations

Question 3 Explanation:

Predictors of dementia in PD include late age of onset, akinetic rigid phenotype, presence of severe depression, persistent hallucinations, and advanced stages of disease

Question 4

Which of the following is not a feature of essential tremor ?

A	Bilaterality
B	Frequency of 8 to 10 Hz
C	Postural dependency
D	Aggravation with alcohol

Question 4 Explanation:

Essential tremor (ET) presentation includes bilaterality, higher frequency (8 to 10 Hz), and postural dependency and significant relief with alcohol.

Question 5

‘Early appearance of hallucinations’ favours which of the following diagnosis ?

A	Parkinson’s disease
B	Wilson ’s disease
C	Cortical dementia with Lewy bodies (DLB)
D	Alzheimer’s disease

Question 5 Explanation:

In DLB, parkinsonian features are compounded by early appearance of hallucinations or druginduced hallucinations and disturbances in arousal and behavior.

Question 6

‘Early imbalance & falls’ favours the diagnosis of ?

A	Parkinson’s disease
B	Progressive supranuclear palsy (PSP)
C	Cortical dementia with Lewy bodies (DLB)
D	Multiple system atrophy (MSA)

Question 6 Explanation:

The development of early imbalance and falls suggests progressive supranuclear palsy (PSP).

Question 7

‘Early urinary incontinence, orthostatic hypotension, and dysarthria’ favours which of the following diagnosis ?

A	Parkinson’s disease
B	Progressive supranuclear palsy (PSP)
C	Cortical dementia with Lewy bodies (DLB)
D	Multiple system atrophy (MSA)

Question 7 Explanation:

The development of early urinary incontinence, orthostatic hypotension and dysarthria suggest multiple system atrophy (MSA).

Question 8

Parkinsonian symptoms develop when striatal dopamine depletion reaches how much of normal ?

A	10 to 30 %
B	30 to 50 %
C	50 to 70 %
D	70 to 90 %

Question 8 Explanation:

Symptoms develop when striatal dopamine depletion reaches 50 to 70 % of normal

Question 9

Which of the following symptoms respond poorly to therapy in PD ?

A	Bradykinesia
B	Abnormal posture
C	Balance difficulties
D	Rigidity

Question 10

Which of the following symptoms respond poorly to therapy in PD ?

A	Cognitive symptoms
B	Abnormal posture
C	Tremor
D	Rigidity

Question 10 Explanation:

Cognitive symptoms, hypophonia, autonomic dysfunction &balance difficulties respond poorly to symptomatic therapy. While, bradykinesia, tremor, rigidity & abnormal posture respond well.

Question 11

Which of the following drugs has neuroprotective function in PD ?

A	Levodopa
B	Bromocryptine
C	Selegiline
D	Amantadine

Question 11 Explanation:

Selegiline in addition to a mild symptomatic effect has a neuroprotective function. High doses of coenzyme Q10, intrastriatal infusion of neurotrophic factors and exercise may be beneficial.

Question 12

Which of the following drugs have the potential of a neuroprotective therapy in PD ?

A	Selegiline
B	Pramipexole
C	Ropinirole
D	All of the above

Question 12 Explanation:

Rasagiline, selegiline, coenzyme Q10, pramipexole, and ropinirole are promising neuroprotection or disease modification agents in PD.

Question 13

Which of the following is false for Dyskinesias in PD ?

A	Choreiform and dystonic movements
B	Occur as a peak dose effect
C	Occur at the beginning or end of the dose
D	None of the above

Question 13 Explanation:

Dyskinesias refer to choreiform and dystonic movements that can occur as a peak dose effect or at the beginning or end of the dose (diphasic dyskinesias).

Question 14

Dopamine agonists act directly on which of the following postsynaptic dopamine receptor ?

A	D1 type
B	D2 type
C	D3 type
D	D4 type

Question 14 Explanation:

Dopamine agonists readily cross the blood-brain barrier and act directly on postsynaptic dopamine receptors - primarily D2 type.

Question 15

Which of the following area of the brain is not protected by the blood-brain barrier (BBB) ?

A	Posterior pituitary gland
B	Pineal gland
C	Area postrema
D	All of the above

Question 15 Explanation:

Four areas of brain are not protected by the blood-brain barrier. These areas include posterior pituitary gland, pineal gland, median eminence of hypothalamus and area postrema. Area postrema (a paired circumventricular organ & vomiting center in medulla) is not covered by BBB because it senses toxins in blood that other parts of brain are protected from. Area postrema triggers nausea & vomiting to prevent further ingestion of toxins.

Question 16

Which of the following statements is false ?

A	Levodopa is a dopamine precursor
B	Dopamine does not cross blood-brain barrier (BBB)
C	Domperidone is a peripheral dopamine-blocking agent
D	None of the above
E	None of the above

Question 17

Levodopa can be combined with ?

A	Carbidopa
B	Benserazide
C	Entacapone
D	All of the above

Question 17 Explanation:

To prevent peripheral metabolism of levodopa to dopamine & development of nausea & vomiting due to activation of dopamine receptors in area postrema, levodopa is used in combination with peripheral decarboxylase inhibitor (carbidopa or benserazide) or COMT inhibitor (tolcapone or entacapone).

Question 18

Which of the following statements about Levodopa is false ?

A	Is a precursor of dopamine
B	It is not metabolized centrally by dopa-decarboxylase
C	It is metabolized peripherally by dopa-decarboxylase
D	It is metabolized by COMT & MAO

Question 18 Explanation:

Levodopa is a precursor of dopamine and is metabolized centrally & peripherally by dopadecarboxylase, catechol-O-methyltransferase (COMT) and monoamine oxidase.

Question 19

Which of the following antiparkinsonian drug is associated with valvular disease ?

A	Levodopa
B	Pergolide
C	Pramipexole
D	Rotigotine

Question 19 Explanation:

Pergolide is associated with asymptomatic valvular disease on chronic administration.

Question 20

Which of the following is not a ‘Dopamine agonist’ ?

A	Levodopa
B	Pergolide
C	Bromocriptine
D	Pramipexole

Question 21

Which of the following dopamine agonist is an ergot derivative ?

A	Bromocriptine
B	Pergolide
C	Cabergoline
D	All of the above

Question 22

Which of the following dopamine agonist is a nonergot derivative ?

A	Pramipexole
B	Ropinirole
C	Rotigotine
D	All of the above

Question 22 Explanation:

Dopamine agonists include ergot alkaloids like bromocriptine, cabergoline, lisuride and pergolide and second generation non-ergot alkaloids like pramipexole, ropinirole and rotigotine

Question 23

Which of the following is administered as a transdermal patch ?

A	Pramipexole
B	Ropinirole
C	Rotigotine
D	Levodopa

Question 23 Explanation:

Rotigotine is administered as a once-daily transdermal patch.

Question 24

Which of the following is used as a rescue agent for treatment of severe “off” episodes ?

A	Apomorphine
B	Ropinirole
C	Pramipexole
D	Levodopa

Question 24 Explanation:

Apomorphine is a dopamine agonist but must be administered parenterally (SC/continuous infusion) and is used as a rescue agent for the treatment of severe “off” episodes.

Question 25

What amount of carbidopa is necessary to block peripheral levodopa decarboxylation into dopamine ?

A	10 mg/day
B	25 mg/day
C	50 mg/day
D	75 mg/day

Question 25 Explanation:

Mostly, 75 mg/day of carbidopa is necessary to block peripheral levodopa decarboxylation into dopamine.

Once you are finished, click the button below. Any items you have not completed will be marked incorrect. Get Results

There are 25 questions to complete.

←

List

→

Return

Shaded items are complete.

1	2	3	4	5
6	7	8	9	10
11	12	13	14	15
16	17	18	19	20
21	22	23	24	25
End

Return

See all quizzes of Parkinson’s Disease (PD) and Other Movement Disorders at here:

Parkinson’s Disease (PD) and Other Movement Disorders- Part 1| Parkinson’s Disease (PD) and Other Movement Disorders- Part 2| Parkinson’s Disease (PD) and Other Movement Disorders- Part 3| Parkinson’s Disease (PD) and Other Movement Disorders- Part 4|Parkinson’s Disease (PD) and Other Movement Disorders- Part 5|Parkinson’s Disease (PD) and Other Movement Disorders- Part 6

1 Which of the following symptom precedes onset of PD ?
A. Rapid eye movement – behavioral disorder (RBD)
B. Micrographia
C. Hypophonia
D. All of the above

2 Cause of neuropsychiatric symptoms in PD can be ?
A. Accompanying Alzheimer’s disease (AD)
B. Accompanying cortical dementia with Lewy bodies (DLB)
C. Side effect of pharmacotherapy
D. All of the above

3 Predictors of dementia in PD include all except ?
A. Early age of onset
B. Akinetic rigid phenotype
C. Presence of severe depression
D. Persistent hallucinations

4 Which of the following is not a feature of essential tremor ?
A. Bilaterality
B. Frequency of 8 to 10 Hz
C. Postural dependency
D. Aggravation with alcohol

5 ‘Early appearance of hallucinations’ favours which of the following
diagnosis ?
A. Parkinson’s disease
B. Wilson ’s disease
C. Cortical dementia with Lewy bodies (DLB)
D. Alzheimer’s disease

6 ‘Early imbalance & falls’ favours the diagnosis of ?
A. Parkinson’s disease
B. Progressive supranuclear palsy (PSP)
C. Cortical dementia with Lewy bodies (DLB)
D. Multiple system atrophy (MSA)

7 ‘Early urinary incontinence, orthostatic hypotension, and
dysarthria’ favours which of the following diagnosis ?
A. Parkinson’s disease
B. Progressive supranuclear palsy (PSP)
C. Cortical dementia with Lewy bodies (DLB)
D. Multiple system atrophy (MSA)

8 Parkinsonian symptoms develop when striatal dopamine
depletion reaches how much of normal ?
A. 10 to 30 %
B. 30 to 50 %
C. 50 to 70 %
D. 70 to 90 %

9 Which of the following symptoms respond poorly to therapy in
PD ?
A. Bradykinesia
B. Abnormal posture
C. Balance difficulties
D. Rigidity
10 Which of the following symptoms respond poorly to therapy in
PD ?
A. Cognitive symptoms
B. Abnormal posture
C. Tremor
D. Rigidity

11 Which of the following drugs has neuroprotective function in PD
?
A. Levodopa
B. Bromocryptine
C. Selegiline
D. Amantadine

12 Which of the following drugs have the potential of a neuroprotective
therapy in PD ?
A. Selegiline
B. Pramipexole
C. Ropinirole
D. All of the above

13 Which of the following is false for Dyskinesias in PD ?
A. Choreiform and dystonic movements
B. Occur as a peak dose effect
C. Occur at the beginning or end of the dose
D. None of the above

14 Dopamine agonists act directly on which of the following
postsynaptic dopamine receptor ?
A. D1 type
B. D2 type
C. D3 type
D. D4 type

15 Which of the following area of the brain is not protected by the
blood-brain barrier (BBB) ?
A. Posterior pituitary gland
B. Pineal gland
C. Area postrema
D. All of the above

16Which of the following statements is false ?
A. Levodopa is a dopamine precursor
B. Dopamine does not cross blood-brain barrier (BBB)
C. Domperidone is a peripheral dopamine-blocking agent
D. None of the above
17 Levodopa can be combined with ?
A. Carbidopa
B. Benserazide
C. Entacapone
D. All of the above

18 Which of the following statements about Levodopa is false ?
A. Is a precursor of dopamine
B. It is not metabolized centrally by dopa-decarboxylase
C. It is metabolized peripherally by dopa-decarboxylase
D. It is metabolized by COMT & MAO

19 Which of the following antiparkinsonian drug is associated with
valvular disease ?
A. Levodopa
B. Pergolide
C. Pramipexole
D. Rotigotine

20 Which of the following is not a ‘Dopamine agonist’ ?
A. Levodopa
B. Pergolide
C. Bromocriptine
D. Pramipexole
21 Which of the following dopamine agonist is an ergot derivative ?
A. Bromocriptine
B. Pergolide
C. Cabergoline
D. All of the above
22 Which of the following dopamine agonist is a nonergot derivative
?
A. Pramipexole
B. Ropinirole
C. Rotigotine
D. All of the above

23 Which of the following is administered as a transdermal patch ?
A. Pramipexole
B. Ropinirole
C. Rotigotine
D. Levodopa

24 Which of the following is used as a rescue agent for treatment of
severe “off” episodes ?
A. Apomorphine
B. Ropinirole
C. Pramipexole
D. Levodopa

25 What amount of carbidopa is necessary to block peripheral levodopa
decarboxylation into dopamine ?
A. 10 mg/day
B. 25 mg/day
C. 50 mg/day
D. 75 mg/day

Parkinson’s Disease (PD) and Other Movement Disorders

[MCQ] Parkinson’s Disease (PD) and Other Movement Disorders- Part 3

I. Start the exam by click the “Start” button

Parkinson’s Disease (PD) and Other Movement Disorders- Part 3

Share this:

Related

[MCQ] Parkinson’s Disease (PD) and Other Movement Disorders- Part 2

[MCQ] Parkinson’s Disease (PD) and Other Movement Disorders- Part 4

You may also like

Leave a Comment Cancel Reply